Avutometinib capsules & Defactinib tablets (AVMAPKI FAKZYNJA CO-PACK) Criteria for Use
July 2026

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

Exclusion Criteria

If ANY of the following are selected, the patient will NOT meet criteria for avutometinib & defactinib.

- ☐ Absolute neutrophil count (ANC) < 1500/mm^3 (unless Duffy null phenotype) or platelets < 100,000/mm^3
- ☐ Moderate or severe hepatic impairment (Child-Pugh class B/C or NCI Organ Dysfunction Working Group Classification)
- ☐ CrCL < 30 ml/min
- ☐ Active or uncontrolled infection
- ☐ Unmanageable drug interaction[1]
- ☐ Symptomatic or unstable brain metastases
- ☐ Ocular disorder defined as history of retinal pathology, active/chronic corneal disorder or history of glaucoma
- ☐ Active skin disorder requiring systemic therapy
- ☐ Pregnancy
- ☐ Lactating

[1] Patients on warfarin were excluded from clinical trial, RAMP-201

Inclusion Criteria

All the following must be selected to meet criteria.

- ☐ Recurrent *KRAS*-mutated low-grade serous ovarian cancer (LGSOC)
- ☐ Progressive disease following at least one prior systemic therapy that included a platinum-based regimen

Additional Inclusion Criteria

All of the following criteria must be selected to meet criteria.

- ☐ Comprehensive ophthalmic exam performed at baseline
- ☐ Able to apply topical corticosteroid to face, scalp, upper chest and upper back daily at therapy initiation and during at least the first 2 cycles; limit unnecessary sun exposure and apply daily sunscreen with SPF $\geq$ 30
- ☐ Care is provided by a VA/VA Community Care oncology provider
- ☐ Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- ☐ Goals of care and role of Palliative Care consult have been discussed and documented

Additional Inclusion Criteria – Select If Applicable

- ☐ For females who can become pregnant and males with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 4 months after stopping treatment
- ☐ For females who are pregnant or plan to become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 1 month after stopping treatment
- ☐ For females who are lactating / providing breastmilk to an infant or planning to do so: Counseling provided on avoiding breastfeeding during therapy and for 2 weeks after stopping treatment.

Original: July 2026

Contact: B. Heron, National Program Manager, VA Pharmacy Benefits Management Services – Formulary Management (12PBM)